Status:
COMPLETED
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
Lead Sponsor:
Pfizer
Conditions:
Growth Hormone Deficiency
Growth Retardation
Eligibility:
All Genders
6+ years
Phase:
PHASE3
Brief Summary
To assess the effect of long-term treatment by Genotonorm on linear growth
Eligibility Criteria
Inclusion
- All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014
- All patients who have stopped during one year will be included if a signed written informed consent
Exclusion
- Endocrine disease, except well substituted hypothyroidism
- Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)
Key Trial Info
Start Date :
February 1 1997
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00174278
Start Date
February 1 1997
End Date
October 1 2006
Last Update
August 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Paris, France